Search

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Macitentan

[L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

Hydromorphone

[A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]

Edoxaban

Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for … By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.

Glatiramer

[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate exhibits several immunomodulatory effects and reduces the relapse rate of relapsing-remitting multiple sclerosis (RRMS) by 30%.

Almonertinib

[A231864] Almonertinib was also approved by the EMA on February 20, 2026.[L56068]

AdimrSC-2f

The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

Iodine povacrylex

Prolonged skin exposure could cause skin defatting manifested by the following signs/symptoms; localized redness, itching, drying and cracking of skin.

Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen